Flow Trader

Stock Market Alert - Despite an ominous sounding note from an analyst on Monday, DNDN continued to soar on Monday, crushing short-sellers and making a mint for DNDN shareholders in the process. In late afternoon trading, the stock is currently up over 27% at $23.05. Volume is extremely high on the session, with over 74 million shares of the stock changing hands so far, compared to a normal daily average of just over 6.6 million shares traded.

Brean Murray Carret & Co. analyst Jonathan Aschoff sounded a note of caution on Monday, saying that an FDA approval would set a dangerous double standard. It should be noted that the company currently has a sell rating on the stock with a price target of $1.50. With the share price soaring, obviously Brean Murray Carret & Co. have been a bit offbase so far on their prediction </end sarcasm>. With DNDN setting new 52 week highs on an almost daily basis and short-sellers getting punished, the big question is, how high will DNDN go?